Introduction:

The SURMOUNT-5 trial is the first head-to-head trial comparing the two very efficacious anti-obesity medications—tirzepatide and semaglutide—in adults with obesity or overweight adults with at least one complication related to obesity. The aim was to evaluate difference in percentage weight loss observed in SURMOUNT-5 trial with 15 mg tirzepatide compared to 2.4 mg semaglutide.

Methods:

1. Design (SURMOUNT-5): Phase 3b, multicentre, randomized, open-label, active-comparator controlled trial.
2. Participants: 751 adults with BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 obesity-related complication.
3. Intervention:
   1. Tirzepatide 10 mg or 15 mg vs. Semaglutide 1.7 mg or 2.4 mg
   2. Weekly subcutaneous administration for 72 weeks.
   3. All participants received lifestyle counselling on diet and exercise.
4. Dose Escalation: Conducted per protocol to reach maximum tolerated dose.
5. Endpoints of this analysis from SURMOUNT-5: Comparison between tirzepatide 15 mg vs semaglutide 2.4 mg from baseline to week 72 for:
   1. Percentage change and absolute change in body weight in kgs
   2. BMI change

Results:

Maximum number of participants in both the treatment groups tolerated the maximum dose of tirzepatide and semaglutide. This analysis will include the participants who tolerated the maximum dose in the SURMOUNT-5 trial to investigate the change in body weight.

Conclusion:

This analysis will demonstrate the reduction in body weight for the doses maximum approved doses of tirzepatide and semaglutide which are 15 mg and 2.4 mg respectively.

ECO, 11-14 May 2025, Malaga, Spain